2019 Global Market of Hepatitis C – Analysis of Antiviral Drugs

1
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial LandscapebyGBI Research

• Explore all reports for  Hepatitis Drugs
  market
• _at_
• http//www.rnrmarketresearch.com/reports/life-scie
  nces/pharmaceuticals/diseases-treatment/hepatitis-
  drugs .

2
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape

• Research Report, has released the pharma report,
  Hepatitis C Therapeutics in Major Developed
  Markets to 2019 Outstanding Recent Approvals and
  Late-Stage Pipeline to Transform Clinical and
  Commercial Landscape. The current Hepatitis C
  treatment landscape consists of a combination of
  pegylated interferon, ribavirin and, in patients
  infected with genotype 1 hepatitis C, one of two
  direct-acting antiviral agents (DAAs). Products
  with these mechanisms of action have performed
  strongly in the commercial setting, with the
  market leader Incivek (a DAA) having reached
  blockbuster sales.
• However, these products are very poorly tolerated
  and only moderately efficacious. The approval of
  the DAA Sovaldi in December 2013 changed this,
  with a complete viral clearance being achieved in
  close to 100 of patients and a much improved
  adverse event profile compared to previous
  standards of therapy. In patients with genotype 2
  and 3 hepatitis C, Sovaldi does not need to be
  administered with pegylated interferon. A number
  of products in the late-stage pipeline, which
  promise to be even more efficacious and safe are
  anticipated to enter the market over the forecast
  period, including several interferon-free
  therapies for genotype 1-infected patients. As a
  result of this, as well as an overall increase in
  the treated population, Researcher believes the
  global market has the potential to grow to a
  value of 18.6 billion by 2019, more than
  tripling the 2012 market value of 5.8 billion.
• Inquire for Discount _at_
• http//www.rnrmarketresearch.com/contacts/discount
  ?rname148416 .

3
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape

• Scope
• A brief introduction to hepatitis C, including
  the diseases pathogenesis, risk factors and
  diagnosis, and detailed analyses of disease
  epidemiology and treatment algorithms.
• In-depth analysis of the major antiviral drugs
  used in the treatment of hepatitis C, including
  analyses of their safety, efficacy, treatment
  patterns and strengths/weaknesses. Includes a
  heat map that compares marketed drugs in terms of
  safety and efficacy.
• A comprehensive review of the pipeline for
  hepatitis C therapies, including individual
  analysis of a number of late-stage pipeline drugs
  that are likely to enter the market during the
  forecast period. The pipeline is analyzed by
  phase distribution, molecule type and molecular
  target.
• In-depth clinical trial enrolment, trial duration
  and program failure rate analyses for each
  molecule type and mechanism of action.
  Additionally, clinical trial endpoints and
  certain selection criteria are analyzed in great
  depth. This section also includes an additional
  heat map regarding pipeline products, and a
  direct cross-analysis against currently marketed
  products.
• Complete Report Available _at_
• http//www.rnrmarketresearch.com/hepatitis-c-thera
  peutics-in-major-developed-markets-to-2019-outstan
  ding-recent-approvals-and-late-stage-pipeline-to-t
  ransform-clinical-and-commercial-landscape-market-
  report.html .

4
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape

• Multi-scenario forecast data of the market to
  2019, which takes into account the effects of the
  introduction of new drugs, the expiry of key
  patents on current drugs and the changes in
  disease epidemiology across the key developed
  markets US, Canada, Japan, Germany, UK, France,
  Italy and Spain.
• Discussion of the drivers and barriers for market
  growth.
• Analysis of licensing and co-development deals
  occurring in the hepatitis C market.
• Reasons to buy
• Understand the different types of hepatitis C
  therapies and how treatment varies by genotype.
• Understand the treatment algorithms and
  guidelines related to hepatitis C, how they are
  anticipated to change during the forecast period
  and where opportunities and unmet needs lie.
• Understand the vast scope of the pipeline,
  including which molecule types and mechanisms of
  action are most prominent.
• Buy a copy of report _at_
• http//www.rnrmarketresearch.com/contacts/purchase
  ?rname148416 .

5
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape

• Observe trends in clinical trial duration and
  size as clinical phase and molecule type varies.
  Use the clinical trial failure rate analysis to
  assess the risk profiles of current and/or future
  developmental programs for hepatitis C
  therapeutics.
• Observe the shift in clinical trial endpoints
  with each clinical Phase, and use this data to
  potentially influence any future developmental
  programs. Additionally, understand the trends in
  enrolment by patient genotype.
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  and the points of opportunity which remain to be
  capitalized upon.
• Table of Contents
• 1 Table of Contents 51.1 List of Tables 81.2
  List of Figures 9
• 2 Introduction 102.1 Signs and Symptoms 102.2
  Etiology and Risk Factors 11
• Request Sample copy of this report _at_
• http//www.rnrmarketresearch.com/contacts/request
  -sample?rname148416 .

6
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape

• For more details contact Mr. Priyank Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.